The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis

References

• Teras LR, DeSantis CE, Cerhan JR, et al. US lymphoid malignancy statistics by World Health Organization subtypes. Ca Cancer J Clin. 2016;66:443–459.
   Google Scholar
• Tilly H, Vitolo U, Walewski J, ESMO Guidelines Working Group al; ESMO Guidelines Working Group, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii78–vii82.
   PubMed Web of Science ®Google Scholar
• Hamadani M, Hari PN, Zhang Y, et al. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1729–1736.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. Jco. 2012;30:4462–4469.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Jco. 2014;32:3048–3058.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4:5.
   PubMed Web of Science ®Google Scholar
• Bari A, Tadmor T, Sacchi S, et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica. 2014;9:125–130.
   Google Scholar
• Cheson BD, Pfistner B, Juweid ME, International Harmonization Project on Lymphoma, et al. Revised response criteria for malignant lymphoma. Jco. 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Roger B. Newson, comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J. 2010;10:339–358.
   Web of Science ®Google Scholar
• Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol. 2011;29:1844–1854.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. Jco. 2005;23:4652–4661.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood. 2010;115:775–777; quiz 918.
   PubMed Web of Science ®Google Scholar
• Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on 18F- fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8:99587–99600.
   PubMedGoogle Scholar
• Toledano MN, Desbordes P, Banjar A, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45:680–688.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49:1745–1751.
   PubMed Web of Science ®Google Scholar
• Bari A, Marcheselli L, Sacchi S, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never ending story. Ann Oncol. 2010;21:1486–1491.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25:1502–1509.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Benyamini N, Avivi I, et al. Absolute monocyte count is associated with adverse prognosis in diffuse large B-cell lymphoma: a validation study in a cohort of 219 patients from two centers. Haematologica. 2012;97:318–326.
   PubMedGoogle Scholar
• Bari A, Tadmor T, Sacchi S, et al. Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. Leuk Res. 2013;37:619–623.
   PubMed Web of Science ®Google Scholar
• Batty N, Ghonimi E, Feng L, et al. The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP. Clin Lymphoma Myeloma Leuk. 2013;13:15–18.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Tomita N, Itabashi M, et al. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era. Eur J Haematol. 2014;92:204–210.
   PubMed Web of Science ®Google Scholar
• Bari A, Tadmor T, Sacchi S, et al. Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy. Br J Haematol. 2014;167:133–136.
   PubMed Web of Science ®Google Scholar
• Lin B, Chen C, Qian Y, et al. Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. Leuk Lymphoma. 2015;56:2563–2568.
   PubMed Web of Science ®Google Scholar
• Marcheselli L, Bari A, Anastasia A, et al. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Br J Haematol. 2015;169:544–551.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Azzaoui I, Uhel F, Rossille D, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128:1081–1092.
   PubMed Web of Science ®Google Scholar
• Ji H, Niu X, Yin L, et al. Ratio of immune response to tumor burden predicts survival via regulating functions of lymphocytes and monocytes in diffuse large B-cell lymphoma. Cell Physiol Biochem. 2018;45:951–961.
   PubMed Web of Science ®Google Scholar